

CURRICULUM VITAE  
**MARK ALLEN O’ROURKE, M.D.**

Signature \_\_\_\_\_

Date \_\_\_\_\_

**BUSINESS ADDRESS**

Prisma Health Upstate Cancer  
Institute (864) 987-7000  
65 International Drive (864) 987-1254  
Greenville, South Carolina 29615 Mark.ORourke@PrismaHelath.org

**Research Administration:** Prisma Health Upstate Cancer Institute  
Research Administration  
3 Butternut Dr., Suite B, Greenville, SC 29605  
Phone (864) 522-2065 Fax (864) 672-7810

**Prisma Health Upstate Cancer Institute**

Clinical Practice Locations: 65 International Drive • Greenville, SC 29615  
200 Andrews Street, Suite 100 • Greenville, SC 29601  
109 Fleetwood Drive, Suite A • Easley, SC 29640  
900 W. Faris Road • Greenville, SC 29605  
340 Medical Parkway, Suite 100 • Greer, SC 29650  
3 Butternut Drive, Suite B • Greenville, SC 29605  
131 Lila Doyle Drive • Seneca, SC 29672  
120 Dillon Drive • Spartanburg, SC 29307

**PERSONAL DATA**

removed

**EDUCATION**

1966-1970 San Marcos High School, Santa Barbara, California  
1970-1974 Stanford University, Stanford, California, B.S. Chemistry  
1978-1982 University of California Los Angeles (UCLA), Los Angeles, CA, M.D.

**MEDICAL TRAINING**

- 1982-1983 Internship, Duke University Medical Center (DUMC), Durham, NC
- 1983-1984 Residency, Internal Medicine, DUMC, Durham, NC
- 1984-1985& 1986-1987 Fellowship, Division of Hematology & Oncology, DUMC, Durham, NC
- 1985-1986 Geriatrics Fellowship in the VA Geriatrics Fellowship Program  
VA Medical Center and Duke University Center for the Study of Aging,  
DUMC, Durham, NC

**EMPLOYMENT EXPERIENCE**

- Prisma Health Upstate Cancer Institute 2012-present  
Greenville, SC
- Hematology & Oncology Associates, L.L.C. 1990-2012  
Cancer Centers of the Carolinas, Greenville, SC
- Durwood Medical Clinic, Inc. 1987-1990  
125 Baldwin Ave., Charlotte, NC

**ACADEMIC APPOINTMENTS**

- Clinical Assistant Professor 2012-Present  
University of South Carolina School of Medicine Greenville,  
Greenville, SC
- Clinical Assistant Professor 2012-Present  
Clemson University School of Health Research  
Clemson University, Clemson, SC
- Medical Director, Center for Integrative Oncology & Survivorship 2012 to 2018  
Greenville Health System University Medical Center  
Author of Survive and Thrive blog, at [blog.ghs.org](http://blog.ghs.org)

**NATIONAL CANCER INSTITUTE RESEARCH**

- SWOG Cancer Research Network 1990-present  
Cancer Survivorship Committee 2012-present  
Symptom Control and Quality of Life Committee 2015-present

|   |              |
|---|--------------|
| Palliative and End-of-Life Care Committee<br>Founding co-chair  | 2018-present |
| NCI Community Oncology Research Program (NCORP)<br>Cancer Care Delivery Research Lead<br>NCORP of the Carolinas | 2014-Present |
| NCI Symptom Management & Health-Related Quality of Life<br>Steering Committee (SxQOL SC)                        | 2015-2022    |
| NCI Community Clinical Oncology Program (CCOP)<br>Investigator, Greenville, SC CCOP                             | 1995-2014    |
| Principle Investigator, Greenville, SC CCOP   | 1995-1996    |
| Investigator, Southeastern Cancer Control<br>Consortium CCOP, Charlotte, NC                                     | 1987-1990    |

### **HOSPICE & PALLIATIVE CARE SERVICE**

|   |           |
|---|-----------|
| April 5-12 & November 9-15, 2005<br>Faculty Scholar, The Program in Palliative Care Education and Practice<br>(PCEP), Harvard Medical School Center for Palliative Care, Boston, MA |           |
| October 12-14, 2005<br>Participant, Palliative Care Leadership Centers Site Visit<br>Program, Hospice of the Bluegrass, Lexington, KY   |           |
| Medical Director, Interim Hospice   | 1996-1998 |
| South Carolina Pain Initiative, Member  | 1997      |
| Medical Director, St. Francis Hospice   | 1991-1995 |
| Medical Director, Triangle Hospice, Durham, NC  | 1986-1987 |
| Cancer Pain Study Committee, Durham VA Medical Center   | 1985-1987 |

### **PROFESSIONAL SERVICE**

|   |           |
|---|-----------|
| South Carolina Department of Health & Human Services<br>Pharmacy & Therapeutics Committee, Member | 2003-2005 |
| South Carolina Cancer Alliance, Founding Member   | 2002-2005 |
| Policy and Advocacy Task Force, Vice Chairman   | 2002-2005 |

|   |              |
|---|--------------|
| Greenville County Medical Society, Member   | 1990-present |
| President   | 2005         |
| Treasurer   | 2004         |
| Secretary   | 2003         |
| Legislative Representative  | 2002-present |
| South Carolina Medical Association, Member  | 1990-present |
| Oncology Representative, Interdisciplinary Council  | 1997-1999    |
| Bioethics Committee Member  |              |
| South Carolina Oncology Society, Member   | 1995-present |
| Secretary   | 1997-1998    |
| South Carolina Cancer Alliance, Founding Member   | 2002-present |
| Policy and Advocacy Task Force, Vice Chairman   | 2002-2005    |
| American Medical Association  | 1987-present |
| American Society for Clinical Oncology (ASCO)   | 1987-present |
| South Carolina Department of Health & Human Services<br>Pharmacy & Therapeutics Committee, Member         | 2003-2005    |
| South Carolina Medicare Part B Carrier Advisory Committee   | 1998-2002    |
| Palmetto GBA, Blue Cross and Blue Shield of South Carolina<br>Columbia, South Carolina, Vice Chairman     | 2002         |
| South Carolina Department of Health and Environmental Control (DHEC)<br>Cancer Control Advisory Committee | 1997-2005    |
| Vice Chairman   | 2002         |
| Greenville Free Clinic, Greenville, SC, Volunteer   | 1995-2018    |
| Catholic Medical Association  | 2002-present |
| Christian Medical Association   | 2000-present |

### **COMMUNITY SERVICE**

|  |           |
|--|-----------|
| Hospice House of Greenville Board, Founding Member | 2003-2012 |
| 113 Mills Avenue, Greenville, SC 29605, Chair      | 2003-2012 |

### **MILITARY EXPERIENCE**

U.S. Navy, Lieutenant, Honorable Discharge 1974-1978  
 Instructor, Naval Nuclear Power School

**Specialty/Board Certification:**

|  |          |            |
|--|----------|------------|
| American Board of Internal Medicine,             | #104166  | 09/11/1985 |
| Board Certified, Oncology                        | #104166  | 11/10/1987 |
| Board Certified, Geriatrics                      | #104166  | 04/20/1988 |
| Board Certified, Hospice and Palliative Medicine | #5000054 | 01/01/2006 |
| Board Certified, Hospice and Palliative Medicine | #104166  | 02/05/2009 |

|  |            |
|--|------------|
| NCI INVESTIGATOR NUMBER:   | #16151     |
| Drug Management and Authorization Section,<br>IDB, CTEP, Division of Cancer Treatment, NCI,<br>Executive Plaza North, Room 707-A,<br>Bethesda, Maryland 20892 (301) 496-5725 |            |
| DEA number:  | AO 1650440 |
| SC Drug Control number:  | 20-P331    |

**Military Service:**

|  |         |
|--|---------|
| Navy R.O.T.C.  | 1970-74 |
| U.S. Navy, Lieutenant, Honorable Discharge<br>Instructor, Naval Nuclear Power School | 1974-78 |

Peer Reviewed Journal Articles, Meeting Abstracts, and Presentations are on the NCBI website at the link below.

[http://www.ncbi.nlm.nih.gov/sites/myncbi/10\\_NxMIW29GAo/bibliography/50403652/public/?sort=date&direction=ascending](http://www.ncbi.nlm.nih.gov/sites/myncbi/10_NxMIW29GAo/bibliography/50403652/public/?sort=date&direction=ascending)

**PUBLICATIONS**

Pooler DB, Ness DB, Sarantopoulos J, Squittieri N, Ravichandran S, Britten CD, Amaravadi RK, Vaishampayan U, LoRusso P, Shapiro GI, Olszanski AJ, Perez R, Gutierrez M, O'Rourke MA, Chung V, Lee JJ, Lewis LD. [The effect of sonidegib \(LDE225\) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.](#) Br J Clin Pharmacol. 2020 Jul 31;. doi: 10.1111/bcp.14508. [Epub ahead of print] PubMed PMID: 32736411.

Burch JB, Ginsberg JP, McLain AC, Franco R, Stokes S, Susko K, Hendry W, Crowley E, Christ A, Hanna J, Anderson A, Hébert JR, O'Rourke MA. [Symptom Management Among Cancer Survivors: Randomized Pilot Intervention Trial of Heart Rate Variability Biofeedback.](#) Appl Psychophysiol Biofeedback. 2020 Jun;45(2):99-108. doi: 10.1007/s10484-020-09462-3. PubMed PMID: 32358782.

O'Rourke MA. [Physician-Assisted Suicide \(PAS\)/Physician Aid in Dying \(PAD\) at the End of the Day](#). *Pract Radiat Oncol*. 2019 Nov;9(6):384-386. doi: 10.1016/j.prro.2019.09.003. Epub 2019 Sep 13. PubMed PMID: 31525425.

Hudson MF, O'Rourke MA, Blackhurst DW, Caldwell J, Horner RD. [Clinical Work Intensity Among Medical Oncologists Practicing in National Community Oncology Research Program Community Sites](#). *J Oncol Pract*. 2019 Oct;15(10):e870-e877. doi: 10.1200/JOP.19.00132. Epub 2019 Jul 23. PubMed PMID: 31335248.

Wirth MD, Franco R, Wagner Robb S, Daniels K, Susko K, Hudson MF, O'Rourke MA. [Randomized Controlled Trial of a 4-Week Mindfulness Intervention among Cancer Survivors Compared to a Breathing Control](#). *Cancer Invest*. 2019;37(4-5):227-232. doi: 10.1080/07357907.2019.1610968. Epub 2019 Jun 14. PubMed PMID: 31198066.

O'Rourke MA, O'Rourke MC, Hudson MF. [Reasons to Reject Physician Assisted Suicide/Physician Aid in Dying](#). *J Oncol Pract*. 2017 Oct;13(10):683-686. doi: 10.1200/JOP.2017.021840. Epub 2017 Aug 29. PubMed PMID: 28850311.

O'Rourke MA. Use of heart rate variability (HRV) biofeedback for symptom management among cancer survivors. American Society of Clinical Oncology 2017 Annual Meeting; 2017 June 2; Chicago, Illinois, USA. *Journal of Clinical Oncology* 2017 35:15\_suppl, 10099-10099; c2017.

Guo Q, Shuford S, McKinley B, Rippon M, Cornett W, O'Rourke M, Schammel D, Edenfield J, Kaplan DL, Crosswell HE, Desrochers T. 4834 / 24 - 3D modeling of immune cell interactions in breast cancer and prediction of immunotherapy response. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. American Association for Cancer Research Annual Meeting 2017; 2017 April 1; Washington D.C., United States. c2017.

O'Rourke MA. Heart rate variability (HRV) training for symptom control in cancer survivors. ASCO Cancer Survivorship Symposium; 2017 January 28; San Diego, California, USA. *Journal of Clinical Oncology* 2017 35:5\_suppl, 148-148; c2017.

O'Rourke MA. 2017 Cancer Survivorship Symposium General Session Prostate Cancer Clinic Case. ASCO Survivorship Symposium 2017. 2017 January; San Diego, California, USA.

Leighton P, O'Rourke MA. Development and Implementation of an Electronic Measurement Process for Survivorship Care Plan Dissemination and Compliance. *J Clin Oncol* 35, 2017 (suppl 5S; abstr 67). 2017 ASCO Cancer Survivorship Symposium; 2017 January 27; San Diego, California, USA. c2017.

O'Rourke MA. Electronically generating the treatment summary (TS) and survivorship care plan (SCP) for cancer survivors from a tumor registry. 2016 ASCO Annual Meeting

Proceedings. 2016 ASCO Annual Meeting; 2016 June 6; Chicago, Illinois, USA. J Clin Oncol 34, 2016 (suppl; abstr 10084); c2016.

Unger JM,...**O'Rourke MA**, et al: Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol. 2016 May;12(10):1219-31. doi: 10.2217/fon-2015-0076. Epub 2016 Mar 8. PubMed PMID: 26952901; PubMed Central PMCID: PMC4864045.

Ligibel JA, ..**O'Rourke MA**, et al: Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. J Clin Oncol. 2015 Nov 20;33(33):3961-7. doi: 10.1200/JCO.2015.63.1440. Epub 2015 Aug 31. Review. PubMed PMID: 26324364.

Smerage JB, ..**O'Rourke MA**, et al: Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. J Clin Oncol. 2014 Jun 2. pii: JCO.2014.56.2561. [Epub ahead of print] PubMed PMID: 24888818.

Saltz L, ..**O'Rourke MA**, et al: A Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4. PubMed PMID: 22055112.

Lampen-Smith A, ..**O'Rourke MA**, et al:Blinded randomized controlled study of the effect of a discharge communication template on proton pump inhibitor prescribing. N Z Med J. 2012 Feb 24;125(1350):30-6. PubMed PMID: 22382254.

Robert NJ,...**O'Rourke MA**, et al: Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat. 2011 Feb;126(1):101-8. Epub 2010 Dec 25. PubMed PMID: 21188632

Reynolds C,...**O'Rourke MA**, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009 Dec 1;27(34):5808-15. Epub 2009 Nov 2. PubMed PMID: 19884554; PubMed Central PMCID: PMC2793001.

Carter DL,...**O'Rourke MA**, et al: Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma. Invest New Drugs. 2008 Oct;26(5):473-81. Epub 2008 May 13. PubMed PMID: 18473121.

Haller DG,...**O'Rourke MA**, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1;23(34):8671-8. PubMed PMID: 16314627.

- Loesch D,...,**O'Rourke MA**, et al.: Phase II Multicenter Trial of a Weekly Paclitaxel and Carboplatin Regimen in Patients with Advanced Breast Cancer. *J Clin Oncol* 2002; 20:3857-3864. PMID: 12228205
- O'Rourke MA**, Loesch D, et al.: Efficacy and tolerability of a weekly Taxol (T) plus Carboplatin (C) regimen in patients <65 years versus ≥ 65 years with advanced breast cancer (ABC). *Proceedings American Society of Clinical Oncology* 2002; 21: 39b, #1967
- Walls J, **O'Rourke MA**, et al.: First-Line Therapy of Taxotere (T) and Navelbine (N) in patients with advanced Non-Small Cell Lung Cancer (NSCLC): a Phase II Study. *Proceedings American Society of Clinical Oncology* 2000; 19 #2158
- Shepard FA, **O'Rourke MA**, et al.: Prospective Randomized Trial of Docetaxel versus Best Supportive Care in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum - Based Chemotherapy. *J Clin Oncol* 2000; 18 (10): 2095-2103 PMID: 10811675
- Sridhar M,..., **O'Rourke MA**, et al: Multicenter Phase II Study to Evaluate a 28-Day Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients with Previously Untreated Metastatic colorectal Cancer. *J clinical Oncology* 2000; 18 (15): 2894-2901 PMID: 10920138
- Kraut E,...,**O'Rourke MA**, et al: A Phase II Study of 9-Amino camptothecin in Patients with Refractory Breast Cancer. *Cancer Investigation* 2000; 18 (1): 28-31 PMID: 10701364
- Schilsky RL,..., **O'Rourke MA**, et al: A Multicenter Phase II Study of a five-day regimen of oral 5-fluorouracil plus Eniluracil with or without Leucovorin in patients with Metastatic colorectal cancer. *Ann Oncol* 2000; 11 (4): 415-20 PMID: 10847459
- O'Rourke MA**, Garfield D, et al: Phase II Trial of Taxotere (T) and Navelbine (N) as first-Line Therapy in Patients (pts) with advanced non-small cell lung cancer (ANSCCL) *Proceedings American Society of Clinical Oncology* 1999; 18 #1999
- Dancy J,...**O'Rourke MA**, et al: Quality of Life (QOL) Assessment in a randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum based chemotherapy. *Proceedings American Society of Clinical Oncology* 1999; 18 #1896
- Sheperd F,...**O'Rourke MA**, et al: Randomized Study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) in patients previously



- treated with platinum-based chemotherapy. Proceedings American Society of clinical Oncology 1999;18 #1784
- Burger RA,...**O'Rourke MA**, et al: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncology 1999; 72 (2): 148-53 PMID: 10021293
- Vogel C,...**O'Rourke MA**, et al: Vinorelbine as first line chemotherapy for advanced breast cancer in women 60 years of age or older. Annals of Oncology 1999; 10: 397-402. PMID: 10370781
- Field-Jones S,...**O'Rourke MA**, et al: Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer. A phase II Trial. Annals of Oncology 1999;10: 1307-1310 PMID: 10631457
- Manis,...**O'Rourke MA**, et al: A Phase II Open-Label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated Metastatic colorectal cancer. Proceedings American Society of Clinical Oncology 1998;17 #1083
- O'Rourke, MA**, Klassy, J.A., et al. An evaluation of a two drug combination of Navelbine and Cisplatinium as Neoadjuvant Therapy for patients presenting with inoperable Stage III A or B Non-Small Cell Lung Cancer (NSCL). Proceedings American Society Clinical Oncology 1997: 16 (submitted)
- Schilsky, R., **O'Rourke, MA**, et al. A Phase II study of a five day regimen of Oral 5-Fluorouracil (5-FU) plus GW776 (776C85) with or without Leucovorin (LV) in patients with Metastatic Colorectal Cancer. Proceedings American Society Clinical Oncology 1997: 16 (submitted)
- O'Rourke MA**, Shalabi A, Webb S: Methadone for Treatment of Cancer Pain. JAMA 1996; 275 (7): 519 Letter.
- Garst M, **O'Rourke MA**, et al: Vinorelbine (NVB) and Carboplatinum for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSVLC): A Phase II Response, Toxicity, and Survival Study. Proceedings American Society Clinical Oncology 1996; 15: 70
- Smalley R, **O'Rourke MA**, et al: An Evaluation of a Two Drug Combination of Navelbine and Cisplatinium as Neoadjuvant Therapy for Patients Presenting with Inoperable Stage III A or B Non Small Cell Lung Cancer CNSLC. Proceedings American Society Clinical Oncology 1996; 15: 1203. 30 -32.

- Crawford J, **O'Rourke MA**, et al: Randomized Trial of Vinorelbine compared with Fluorouracil plus Leucovorin in patients with Stage IV Non-Small Cell Lung Cancer. *L Clin Oncol*. 1996 14 (ID): 2774-2784.
- Crawford J, **O'Rourke MA**, et al: Sequential Trials of Vinorelbine (Navelbine) with Carboplatin in Patients with Advanced Non Small Cell Lung Cancer. *Proceedings American Society Clinical Oncology* 1995; 14:1162.
- Jones S, **O'Rourke MA**, et al: A Randomized Comparison of Navelbine (Vinorelbine) and Alkeran (Melphalan) in Anthracycline-Refractory Advanced Breast Cancer. *Journal of Clinical Oncology* 1995; 13:2567-2574.
- Williamson SK, **O'Rourke MA**, et al: Phase II Evaluation of Didemnin B in Hormonally Refractory Metastatic Prostate Cancer. *Investigational New Drugs* 1995; 13: 167-170.
- Jones S, **O'Rourke MA**, et al.: A Multicenter Randomized Trial of IV Navelbine vs. IV Alkeran in Patients with Anthracycline-Refractory Advanced Breast Cancer. *Proceedings American Society Clinical Oncology* 1994; 13: 216.
- Crawford J, **O'Rourke MA**, et al.: A Phase I/II Trial of Dose Escalation of Navelbine Patients with Advanced Non Small Cell Lung Cancer (NSLC). *Proceedings American Society Clinical Oncology* 1994; 13: 1176.
- Muss HB, **O'Rourke MA**, et al.: Tamoxifen versus High Dose Oral Medroxyprogesterone with Metastatic Breast Cancer. A Piedmont Oncology Association (POA) Study. *Journal of Clinical Oncology* 1994; 12 (8): 1630-1638.
- Hazuka MB, **O'Rourke MA**, et al.: Daily Low-Dose Cisplatin Plus Concurrent High-Dose Thoracic Irradiation in Locally Advanced Unresectable Non-Small Cell Lung Cancer: Results of a Phase II Southwest Oncology Group Study. *Journal of Clinical Oncology* 1994; 12 (9): 1814-1820.
- Crawford J,...**O'Rourke MA**, et al: Vinorelbine (Navelbine)/ Carboplatin combination therapy. Dose intensification with granulocyte colony-stimulating factor. *Semin Oncology* 1994; 21 (5 suppl 10): 738
- Wilding G, **O'Rourke MA**, et al.: Phase II Trial of Navelbine In Metastatic Renal Cancer. *Proceedings American Society Clinical Oncology* 1993; 12: 798.
- O'Rourke MA**, et al.: Survival Advantage For Patients with Stage IV NSCLC treated with Single Agent Navelbine in a Randomized Controlled Trial. *Proceedings American Society of Clinical Oncology* 1993; 12: 1148.

Cruz J,..., **O'Rourke MA**, et al.: Menogaril in the Treatment of Relapsed Multiple Myeloma. *Investigational New Drugs* 10: 35-37, 1992.

Muss H, **O'Rourke MA**, et al.: Tamoxifen (CT) Versus High-Dose Oral Medroxyprogesterone Acetate (MPA) As First Line Endocrine Therapy (RX) for Metastatic Breast Cancer (MBC): A Randomized Trial of the Piedmont Oncology Association. *Proceedings American Society Clinical Oncology* 1991;10:30.

Combs MR,...**O'Rourke MA**, et al: An acute-anti-M causing hemolysis in vitro. *Transfusion* 1991; 31 (8) 756-8

Atkins JN,...**O'Rourke MA**, et al: High-Dose 24-hour infusion of 5-fluorouracil in Metastatic prostate cancer. A Phase II trial of the Piedmont Oncology Association. *American Journal Clinical Oncology* 1991;14 (6): 526-9

Atkins JN, **O'Rourke MA**: High-dose 5-Fluorouracil (5-FU) for Hormone Refractory Advanced Prostate Cancer (APC): A Phase II Trial of the Piedmont Oncology Association. *Proceedings American Society Clinical Oncology* 1990; 9: 554.

Powell BL, **O'Rourke MA**: Combination Carboplatin (CBDCA) and Cisplatin (CDDP) for advanced Squamous Cell Carcinoma Of the Head and Neck (SCHN). *Proceedings American Society Clinical Oncology* 1990; 9: 693.

**O'Rourke MA**, Combs MR, Telen MJ: An Example of In Vitro Hemolytic Auto-Anti-M. *Transfusion* 1989; 29: 185, #S50.

Crawford J, **O'Rourke MA**, Cohen HJ: Age Factors in the Management of Lung Cancer. In Yancik R. and Yates J.W. (Eds.): *Cancer in the Elderly Approaches to Diagnosis and Treatment*. New York, Springer Publishing Co., 1989; 177-203.

**O'Rourke MA**, Crawford J: Lung Cancer in the Elderly. *Comprehensive Therapy* 1988; 14(6):47-54.

Crawford J, **O'Rourke MA**, Robertson J: Age Factors in Lung Cancer. *Proceedings American Society Clinical Oncology* 1988; 7: 215.

**O'Rourke MA**, Cohen JH: Anemia in the Elderly. In Ham RH (Ed): *Geriatric Medicine Annual*: 1987. Ordell, New Jersey, Medical Economics Book, 1987.

**O'Rourke MA**, Laszlo J: Age Trends in Lung Cancer Stage and Histology: Implications for Screening (Abstract, American Geriatrics Society, November 19, 1987).

**O'Rourke MA**, Crawford J: Lung Cancer in the Elderly. *Clinics in Geriatric Medicine*, 1987; 3 (4): 595-624.

**O'Rourke MA**, Feussner Jr. FP, Laszlo J: Age Trends of Lung Cancer Stage at Diagnosis: Implications for Lung Cancer Screening of the Elderly. *JAMA* 1987;258:921-926.

**O'Rourke MA**, Cohen JH: Multiple Myeloma in the Elderly. *Medical Grand Rounds*,4(1):30-44,1986

**O'Rourke MA**: Nursing Home Placement and the Demented Patient (Letter). *Annals of Internal Medicine* 1986; 104: 582.